.Attribute Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective calls for addition of patients with MASLD and also measurement of liver outcomes in cardio-- renal-- metabolic trials, when records advise mechanistically probable advantages and also medical safety-- as well as details factors to consider for trial layout and regulatory commendation.